Human Kidney Tubule-Specific Gene Expression Based Dissection of Chronic Kidney Disease Traits

[1]  Matthias Kretzler,et al.  Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Y. Ko,et al.  MICROVASCULAR COMPLICATIONS — NEPHROPATHY ( M AFKARIAN , SECTION EDITOR ) Precision Medicine Approaches to Diabetic Kidney Disease : Tissue as an Issue , 2017 .

[3]  G. Tse,et al.  Animal models for the study of primary and secondary hypertension in humans , 2016, Biomedical reports.

[4]  Yi Luan,et al.  Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study , 2016, The Lancet.

[5]  Shinya Yamamoto,et al.  Severity and Frequency of Proximal Tubule Injury Determines Renal Prognosis. , 2016, Journal of the American Society of Nephrology : JASN.

[6]  M. Stegall,et al.  Predicting Individual Renal Allograft Outcomes Using Risk Models with 1-Year Surveillance Biopsy and Alloantibody Data. , 2016, Journal of the American Society of Nephrology : JASN.

[7]  K. Reidy,et al.  Deletion of Lkb1 in Renal Tubular Epithelial Cells Leads to CKD by Altering Metabolism. , 2016, Journal of the American Society of Nephrology : JASN.

[8]  B. Conway,et al.  An Update on the Use of Animal Models in Diabetic Nephropathy Research , 2016, Current Diabetes Reports.

[9]  A. Więcek,et al.  C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  S. Tatsunami,et al.  Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD , 2016, Clinical and Experimental Nephrology.

[11]  K. Shedden,et al.  Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker , 2015, Science Translational Medicine.

[12]  P. Mount,et al.  Balancing the energy equation for healthy kidneys , 2015, The Journal of pathology.

[13]  K. Ohashi,et al.  Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy , 2015, Diabetes/metabolism research and reviews.

[14]  D. de Zeeuw,et al.  Renal end points in clinical trials of kidney disease , 2015, Current opinion in nephrology and hypertension.

[15]  Y. Ko,et al.  Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD. , 2015, Journal of the American Society of Nephrology : JASN.

[16]  C. Zeng,et al.  Renal histologic changes and the outcome in patients with diabetic nephropathy. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  Kumar Sharma,et al.  Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development , 2014, Nature Medicine.

[18]  J. Coresh,et al.  GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  A. Cheung,et al.  GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  Benjamin J. Keller,et al.  Integrative biology identifies shared transcriptional networks in CKD. , 2014, Journal of the American Society of Nephrology : JASN.

[21]  Xiao-ming Meng,et al.  Inflammatory processes in renal fibrosis , 2014, Nature Reviews Nephrology.

[22]  O. Troyanskaya,et al.  Defining cell-type specificity at the transcriptional level in human disease , 2013, Genome research.

[23]  G. Becker,et al.  Animal models of chronic kidney disease: useful but not perfect. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  P. Clemons,et al.  Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.

[25]  A. Eddy,et al.  Investigating mechanisms of chronic kidney disease in mouse models , 2012, Pediatric Nephrology.

[26]  Glenda C Gobe,et al.  Biomarkers in chronic kidney disease: a review. , 2011, Kidney international.

[27]  K. Suszták,et al.  Transcriptome Analysis of Human Diabetic Kidney Disease , 2011, Diabetes.

[28]  K. Sharma,et al.  Antifibrotic treatment and other new strategies for improving renal outcomes. , 2011, Contributions to nephrology.

[29]  J. Navarro-González,et al.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy , 2011, Nature Reviews Nephrology.

[30]  J. Wetzels,et al.  The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[31]  Li Yang,et al.  Urinary Neutrophil Gelatinase-Associated Lipocalin: A Potential Biomarker for Predicting Rapid Progression of Drug-Induced Chronic Tubulointerstitial Nephritis , 2010, The American journal of the medical sciences.

[32]  Jai Radhakrishnan,et al.  Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[33]  R. Star,et al.  Major contribution of tubular secretion to creatinine clearance in mice. , 2010, Kidney international.

[34]  C. Alpers,et al.  Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[35]  T. Ravasi,et al.  Pirfenidone is renoprotective in diabetic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.

[36]  D. Bolignano,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[37]  Audrey Kauffmann,et al.  Bioinformatics Applications Note Arrayqualitymetrics—a Bioconductor Package for Quality Assessment of Microarray Data , 2022 .

[38]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[39]  C. Marcantoni,et al.  A perspective on arterionephrosclerosis: from pathology to potential pathogenesis. , 2007, Journal of nephrology.

[40]  Tom Greene,et al.  Surrogate end points for clinical trials of kidney disease progression. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[41]  Richard J. Johnson,et al.  Tubulointerstitial damage and progression of renal failure. , 2005, Kidney international. Supplement.

[42]  S. Mackensen,et al.  Relationship between glomerular lesions, serum creatinine and interstitial volume in membrano-proliferative glomerulonephritis , 1977, Klinische Wochenschrift.

[43]  A. Fukamizu,et al.  Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. , 2004, The American journal of pathology.

[44]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[45]  Joseph P Grande,et al.  Correlation of Quantitative Digital Image Analysis with the Glomerular Filtration Rate in Chronic Allograft Nephropathy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[46]  Yung-Ming Chen,et al.  Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. , 2002, Journal of the American Society of Nephrology : JASN.

[47]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[48]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[49]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[50]  R. Meyer,et al.  Creatinine assay by the fuller's earth procedure or by enzymatic determination is adequate for urine but not plasma of mice. , 1993, Comparative biochemistry and physiology. B, Comparative biochemistry.

[51]  G. Müller,et al.  The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. , 1990, Pathology, research and practice.